ML-007

ML-007 is a selective muscarinic acetylcholine M₁ and M₄ receptor agonist which is under development for the treatment of schizophrenia, psychotic disorders, and dyskinesias.¹²³⁴⁵⁶ It is being developed in combination with a peripherally selective muscarinic acetylcholine receptor antagonist (also known as ML-007/peripherally acting anticholinergic or ML-007/PAC).²⁵⁴ The drug is taken orally.¹

It produces antipsychotic-like effects in rodents, including inhibition of amphetamine and phencyclidine (PCP)-induced hyperlocomotion and activity in the conditioned avoidance response test.⁶ These effects appear to dependent on activation of both muscarinic acetylcholine M₁ and M₄ receptors.⁶ The drug is approximately 10-fold more potent than xanomeline in these tests.⁶

As of January 2024, ML-007 is in phase 1 clinical trials for schizophrenia, psychotic disorders, and dyskinesias.¹³⁴ It is under development by MapLight Therapeutics.¹³ The drug is a small molecule, but its chemical structure does not seem to have been disclosed.⁵¹³